SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
新闻
GILD
--
0.00%
--
COVID-19: Gilead's Remdesivir Might Be As Good As It Gets
Seeking Alpha - Article · 4小时前
What Are the Implications of Gilead’s Increased Focus on Oncology? 5-Star Analyst Weights In
Gilead Sciences (GILD) isn’t a one-trick pony. While the news coverage has largely fixated on its potential COVID-19 treatment, remdesivir, the large-cap has an increasingly diverse pipeline.In addition to the headline grabbing remdesivir, Gilead is the bigges
TipRanks · 7小时前
Gilead Sciences (GILD) Leads Search for COVID-19 Vaccine
Insider Monkey · 15小时前
Is Remdesivir a Disappointment?
Motley Fool · 15小时前
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales
Zacks · 16小时前
The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3)
Benzinga · 19小时前
Better Buy: Bristol Myers Squibb vs. Gilead Sciences
Motley Fool · 19小时前
Gilead and Galapagos' filgotinib shows sustained benefit in RA studies
Seeking Alpha - Article · 20小时前
MEDIA-Gilead says Indian licensees are free to price Remdesivir - Economic Times
Reuters · 20小时前
Biotech Stocks: Buy This, Not That
MotleyFool.com · 20小时前
Gilead Says Indian Licensees are Free to Set Price of Remdesivir
-Economic Times https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-licensees-free-to-price-remdesivir-gilead/articleshow/76185458.cms
Economic Times · 21小时前
Gilead, Galapgos Announce Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in Finch 1 and 3 Studies in Rheumatoid Arthritis
Gilead Sciences, Inc.
Benzinga · 21小时前
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis
Business Wire · 1天前
GlaxoSmithKline’s Promising Drug Pipeline Should Boost Stock
marketwatch.com · 1天前
Galapagos shares rise on Phase 3 studies of arthritis drug it's making with Gilead
marketwatch.com · 1天前
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Zacks · 1天前
Wait for More Clarity Before Buying Gilead Stock, Says Analyst
TipRanks · 1天前
Why Gilead's Coronavirus Drug Could Be A Mega Blockbuster: Analyst
Investor's Business Daily · 1天前
Gilead's remdesivir could see $7 billion in annual sales on stockpiling boost: analyst
Reuters · 1天前
Gilead Analyst: Coronavirus Drug, Arcus Collaboration Make Biopharma A Buy
Benzinga · 1天前